PAT 1251

Drug Profile

PAT 1251

Alternative Names: PAT-1251

Latest Information Update: 24 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PharmAkea Therapeutics
  • Class Small molecules
  • Mechanism of Action LOXL2 protein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Idiopathic pulmonary fibrosis

Most Recent Events

  • 22 Aug 2017 PharmAkea completes the phase I trial in Idiopathic pulmonary fibrosis (In volunteers) in United Kingdom (PO)
  • 22 Aug 2017 PharmAkea plans a phase II proof-of-concept trial for Idiopathic pulmonary fibrosis in early 2018
  • 01 Jul 2016 Phase-I clinical trials in Idiopathic pulmonary fibrosis (In volunteers) in United Kingdom (PO, liquid) (NCT02852551)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top